Dr. David Gregory Kornguth, MD

Dr. Kornguth practices at Golden Gate Urology Inc in San Francisco, California.

Dr. Kornguth's NPI, 1801820394, was assigned on July 10, 2006. Dr. Kornguth graduated from Boston University School Of Medicine in 2001. Dr. Kornguth holds California license A104635.

Dr. Kornguth's primary practice is Golden Gate Urology Inc, at 1661 Mission St, San Francisco, CA 94103 in San Francisco County. The practice phone is (415) 543-2830.

Dr. Kornguth's primary practice is Golden Gate Urology Inc in San Francisco, California. Dr. Kornguth is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is Unio Specialty Care, Urology, Encinitas (formerly Genesis Healthcare Partners). Dmand AI also links Dr. Kornguth to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kornguth practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Kornguth's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Kornguth is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Kornguth's licenses on file in 2 states: California and Texas.

Dmand AI lists bladder cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Kornguth treats.

CMS data shows 8,195 Medicare services from Dr. Kornguth across 18 procedure codes in 2024, for 208 Medicare patients. Medicare paid $1,986,956 for them. Every service was in an office.

CMS counts 208 Medicare patients who saw Dr. Kornguth in 2024. The largest group is 75 to 84, with 97 patients. 75% of them have cancer, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kornguth's median patient age at 74, with 3% women.

In 2024, Dr. Kornguth wrote 909 Medicare Part D claims for 248 patients. 93% of them were for generic drugs. CMS names the drug for 851 of them, across 11 drugs with 11 or more claims each, at $310,305 in total drug cost. In 2023, CMS named 1,068 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Kornguth for performance year 2024, reported as part of a group. Dr. Kornguth accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kornguth as offering telehealth.

Dmand AI links 10 papers to Dr. Kornguth, published from 2007 to 2019. 2009 was the busiest year, with 2. The most frequent topics are Radiotherapy Dosage, Monte Carlo Method and Neoplasms, Radiation-Induced. Dr. Kornguth has published most often in Phys Med Biol. Dr. Kornguth's most frequent co-authors are Anita Mahajan, MD, Kenneth D. Aldape, MD and Ka Wah Chan, MD.

CMS Open Payments shows 410 general payments to Dr. Kornguth from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 40% of the total. Boston Scientific Corporation paid the most, $22,617.

Dmand AI lists 1 award for Dr. Kornguth, most recently CMS Stage 1 EHR in 2013.

Dr. Kornguth graduated from Boston University School Of Medicine in 2001.

Dr. Kornguth is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.